Akeso’s Ivonescimab Reaches Fourth Breakthrough in China for Triple-Negative Breast Cancer
November 3, 2025 — 13:45 CST
This Data Is Locked!
This area is available only to Subscribers.
Akeso disclosed that its ivonescimab, a leading bispecific antibody, earned Breakthrough Therapy Designation (BTD) from China's NMPA for the first-line treatment of TNBC alongside chemotherapy.... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
